ArticleFrontiers in medicine2021
COVID-19 Pandemic and Trends in Clinical Trials: A Multi-Region and Global Perspective.
Article in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Effects of benfotiamine treatment over 12 months on morphometric, neurophysiological and clinical measures in type 2 diabetes patients with symptomatic polyneuropathy: a randomized, placebo-controlled, double-blind clinical trial (BOND study).BMJ open diabetes research & care · 2026Trial
- The ClinicalTrials.gov Landscape of Multiple Myeloma Clinical Trials: A 20-Year Analysis of Geographic Distribution and Growth Patterns: USMIRC Analysis.Current oncology (Toronto, Ont.) · 2026Article
- Article
- Navigating Complexities In Randomized Trials: Insights From The EMERGE Trial Amidst Pandemic And Cybersecurity Threat.HRB open research · 2025Article
- Characteristics of pediatric interventional drug trials registered between 2015 and 2024 on ClinicalTrials.gov.Frontiers in pediatrics · 2025Article
- BMScope: A scoping review to chart the evolving clinical study landscape in brain and leptomeningeal metastasis.Neuro-oncology · 2024Article
- Trends in Israeli clinical trials registration "MyTrial".Israel journal of health policy research · 2024Article
- Patient recruitment into clinical studies of solid malignancies during the COVID-19 pandemic in a tertiary cancer center.Neoplasia (New York, N.Y.) · 2023Article
- Impact of the COVID-19 pandemic on the conduct of non-COVID-19 clinical trials: protocol for a scoping review.BMJ open · 2023Article
- Issues with Tissues: Trends in Tissue-Engineered Products in Clinical Trials in the European Union.Tissue engineering. Part B, Reviews · 2023Review
- Impact of COVID-19 on Cancer-Related Care in the United States: An Overview.Current oncology (Toronto, Ont.) · 2023Review
- Technologies and therapeutics for ongoing prevention of respiratory infections.Clinical & translational immunology · 2023Article
- Conducting a supportive oncology clinical trial during the COVID-19 pandemic: challenges and strategies.Trials · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To evaluate the effect of the COVID-19 pandemic on clinical development, the number of newly started clinical trials in each geographical region between January 2018 and December 2020 were calculated based on data from the ClinicalTrials.gov database. Data regarding new drug applications were obtained from European Medicines Agency monthly reports, pharmaceutical company press releases, and the archives of the Drugs.com database. The mean percentage change in newly started clinical trials for diseases other than COVID-19 between each month in 2019 and the corresponding month in 2020 was -7.5%, with the maximum of -57.3% observed between April 2019 and April 2020. Similarly, the mean percentage change of reported results for each month in 2019 and 2020 was -5.1%, with the maximum of -27.4% observed in July 2020. The activity of clinical trials was decreased as the number of COVID-19 patients was increased, and a statistically negative correlation was observed between the prevalence of COVID-19 and the percentage decrease in the number of clinical trials stared or reported results. As for new drug submissions, decreases were observed in the latter half of 2020 compared with the same period during the previous year, for each indicator. A considerable decline in non-COVID-19 activity for all indicators regarding clinical developments was suggested during the first wave of the COVID-19 pandemic. It is important to recognize the situation and continue to make efforts to conduct clinical trials for both COVID-19 and no-COVID-19 for new medical developments in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.